Back to top

BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability

Biomarin Pharmaceutical Inc. ($BMRN) announced an update on their ongoing clinical study. BioMarin (BMRN) has launched IMPALA, a Phase 4 study titl...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)